I'm really pleased to be joined by the Regeneron team. Next to me is Chris ... is the best way to deliver long-term shareholder value is continuing to invest in our own internal R&D capabilities.

Ohtuvayre's rapid US launch boosts Verona's growth with Q1 2025 sales up 95%. Read more on VRNA stock's blockbuster potential ...

Twenty-seven states and Washington, D.C. are suing to stop 23andMe (ME) from selling customers’ personal information without ...

Me was founded in 2006 and pioneered the direct-to-consumer genetic testing model. Customers responded positively, ordering ...

Public exchange offer for all shares of CureVac where each share of CureVac will be exchanged for approx. $5.46 in BioNTech American Depositary Shares (“ADSs”), representing a premium of 55% to ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ...

AI data centers need energy, and that’s what’s made the stock price of aptly-named NRG $NRG rise 88% in the past year ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM) is one of the 13 Biotech Stocks with Huge Upside Potential. The FDA’s Division of ...

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /CNW/ — Equity Insider News Commentary – The 2025 ASCO Annual Meeting has ...